{
    "clinical_study": {
        "@rank": "161491", 
        "arm_group": {
            "arm_group_label": "ABT-199", 
            "arm_group_type": "Experimental", 
            "description": "ABT-199 monotherapy"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1, open-label, multicenter, extension study.  Subjects with non-Hodgkin's\n      lymphoma (NHL) (excluding chronic lymphocytic lymphoma [CLL], small lymphocytic lymphoma\n      [SLL], and mantle cell lymphoma [MCL]) who completed a prior ABT-199 study, or were active\n      and assigned to ABT-199 when the study was completed, may roll over into this extension\n      study.  Subjects will receive ABT-199 during this study."
        }, 
        "brief_title": "An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has completed a prior ABT-199 study (and had met the criteria for a diagnosis\n             of NHL and all other eligibility criteria for the previous study) and the\n             investigator believes that treatment with ABT-199 is in the best interest of the\n             subject.\n\n        Exclusion Criteria:\n\n          -  Subject discontinued ABT-199 administration before completing the prior study (due to\n             disease progression, toxicity, withdrawn consent, other).\n\n          -  Subject has any medical condition that in the opinion of the investigator places the\n             subject at an unacceptably high risk for toxicities.\n\n          -  Subject has not recovered to \u2264 Grade 2 clinically significant adverse\n             effect(s)/toxicity(ies) of previous therapy.\n\n          -  Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease (PTLD),\n             Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic\n             lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma\n             (MCL)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969695", 
            "org_study_id": "M13-835"
        }, 
        "intervention": {
            "arm_group_label": "ABT-199", 
            "description": "ABT-199 continuous once daily dosing", 
            "intervention_name": "ABT-199", 
            "intervention_type": "Drug", 
            "other_name": "GDC-0199"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "non-Hodgkin's lymphoma", 
            "GDC-0199", 
            "Safety", 
            "Relapsed", 
            "Refractory", 
            "ABT-199", 
            "Cancer"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724-5024"
                    }, 
                    "name": "Site Reference ID/Investigator# 101359"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756-0001"
                    }, 
                    "name": "Site Reference ID/Investigator# 92596"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Site Reference ID/Investigator# 101417"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Site Reference ID/Investigator# 101357"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Justin L. Ricker, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study", 
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study"
            }, 
            {
                "description": "Subjects will be monitored for clinical and laboratory evidence of adverse events throughout the study", 
                "measure": "Percentage of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study"
            }, 
            {
                "description": "Body temperature, weight, blood pressure, heart rate", 
                "measure": "Change in physical exam finding, including vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from Day 1 up to 2 years after the last subject has enrolled in the study"
            }, 
            {
                "description": "Chemistry, coagulation, hematology, lymphocyte enumeration, paraproteins, urinalysis, and, if appropriate, viral polymerase chain reaction and viral serologies", 
                "measure": "Change in clinical laboratory test results", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from Day 1 up to 2 years after the last subject has enrolled in the study"
            }, 
            {
                "description": "Electrocardiogram and Multi Gated Acquisition Scan and/or Echocardiogram", 
                "measure": "Change in cardiac assessment findings", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from Day 1 up to 2 years after the last subject has enrolled in the study"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969695"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}